Compare PMAX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PMAX | PPCB |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.8M |
| IPO Year | 2024 | 2011 |
| Metric | PMAX | PPCB |
|---|---|---|
| Price | $1.11 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.8K | ★ 120.1K |
| Earning Date | 05-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.06 |
| 52 Week High | $5.20 | $6.79 |
| Indicator | PMAX | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 27.66 | 41.61 |
| Support Level | $0.24 | $0.74 |
| Resistance Level | $2.69 | $1.26 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 11.66 | 24.62 |
Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.